Skip to content

Drug interactions

Irinotecan + Ustekinumab

Severity: Minor

Irinotecan and Ustekinumab: minor interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Irinotecan is metabolized by CYP3A4 and UGT1A1, and its toxicity is substantial. Ustekinumab could theoretically alter CYP3A4 activity via cytokine changes, but no clinical effect is established.

What this interaction means in plain words

Irinotecan and Ustekinumab have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.

Irinotecan belongs to Oncology; Ustekinumab belongs to Gastrointestinal Tract.

Evidence level: Low

Why it happens

Theoretical normalization of cytokine-suppressed CYP3A4 activity.

What to do

Monitor for neutropenia and diarrhea as routine during irinotecan therapy, particularly when ustekinumab is started or stopped.

What to ask your pharmacist

  • Is there anything I should notice while taking both?
  • Do I need to tell my doctor at the next visit?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Irinotecan and Ustekinumab, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Irinotecan with Ustekinumab?

MediHelp rates the interaction as minor. Irinotecan and Ustekinumab have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Irinotecan is metabolized by CYP3A4 and UGT1A1, and its toxicity is substantial. Ustekinumab could theoretically alter CYP3A4 activity via cytokine changes, but no clinical effect is established.

How serious is the interaction between Irinotecan and Ustekinumab?

MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for neutropenia and diarrhea as routine during irinotecan therapy, particularly when ustekinumab is started or stopped.

What other medicines interact with Ustekinumab?

MediHelp also lists interactions of Ustekinumab with, for example, Bcg vaccine live, Typhoid vaccine live, Adalimumab. The full list is on the Ustekinumab page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in